teaser
Sitagliptin (Januvia), a new drug for the treatment of diabetes, has received a positive opinion from the CHMP and the EMEA, and could get full approval from the EMEA as soon as April.
This drug is the first in a new class of drugs called dipeptidyl peptidase-4 inhibitors. The FDA gave sitagliptin the green light in October 2006 as monotherapy and as add-on therapy to either metformin or thiazolidinediones to improve blood glucose control in patients with type 2 diabetes, when diet and exercise are not enough.
